Ignite Creation Date:
2025-12-24 @ 3:44 PM
Ignite Modification Date:
2026-01-27 @ 3:05 AM
Study NCT ID:
NCT01953692
Status:
COMPLETED
Last Update Posted:
2021-08-04
First Post:
2013-09-26
Is Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Trial of Pembrolizumab (MK-3475) in Participants With Blood Cancers (MK-3475-013/KEYNOTE-013)
Sponsor:
Merck Sharp & Dohme LLC
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2013-11-22
Start Date Type:
ACTUAL
Primary Completion Date:
2020-06-26
Primary Completion Date Type:
ACTUAL
Completion Date:
2020-06-26
Completion Date Type:
ACTUAL
First Submit Date:
2013-09-26
First Submit QC Date:
None
Study First Post Date:
2013-10-01
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
2021-06-15
Results First Submit QC Date:
None
Results First Post Date:
2021-07-12
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-08-02
Last Update Post Date:
2021-08-04
Last Update Post Date Type:
ACTUAL